|
| 36550020 | Non-synonymous, synonymous, and non-coding nucleotide variants contribute to recurrently altered biological processes during retinoblastoma progression. | Genes Chromosomes Cancer | 2023 |
| 37199745 | Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies. | Cancer Chemother Pharmacol | 2023 |
| 35211994 | Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance. | EMBO J | 2022 |
| 35947641 | Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function. | Cancer Res | 2022 |
| 33323683 | The O6-methyguanine-DNA methyltransferase inhibitor O6-benzylguanine enhanced activity of temozolomide + irinotecan against models of high-risk neuroblastoma. | Anticancer Drugs | 2021 |
| 33578855 | Neuroblastoma Invasion Strategies Are Regulated by the Extracellular Matrix. | Cancers (Basel) | 2021 |
| 34408079 | ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156. | Sci Transl Med | 2021 |
| 33079733 | Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies. | Anticancer Drugs | 2021 |
| 33423090 | A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors. | Cancer Chemother Pharmacol | 2021 |
| 33332735 | Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor. | EMBO Mol Med | 2021 |
| 32409685 | MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma. | Cell Death Dis | 2020 |
| 31637848 | miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma. | Mol Oncol | 2020 |
| 30272587 | Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia. | Anticancer Drugs | 2019 |
| 31780656 | The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status. | Nat Commun | 2019 |
| 31693904 | Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. | Cell Rep | 2019 |
| 31484706 | Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical Models. | Mol Cancer Ther | 2019 |
| 30952988 | Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. | Nat Biomed Eng | 2019 |
| 30836314 | Hydrophilic interaction liquid chromatography-tandem mass spectrometric approach for simultaneous determination of safingol and D-erythro-sphinganine in human plasma. | J Chromatogr B Analyt Technol Biomed Life Sci | 2019 |
| 30563935 | Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models. | Clin Cancer Res | 2019 |
| 28921800 | Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. | Pediatr Blood Cancer | 2018 |
| 29967609 | A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. | Front Immunol | 2018 |
| 30046297 | Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. | Front Immunol | 2018 |
| 30251395 | Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines. | Pediatr Blood Cancer | 2018 |
| 29769286 | Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma. | Sci Transl Med | 2018 |
| 29603591 | Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. | Pediatr Blood Cancer | 2018 |
| 27650817 | Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. | Pediatr Blood Cancer | 2017 |
| 28340497 | P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models. | Int J Cancer | 2017 |
| 28429653 | Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives. | Exp Biol Med (Maywood) | 2017 |
| 28350380 | Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. | Sci Data | 2017 |
| 28420721 | Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial. | Clin Cancer Res | 2017 |
| 28119491 | Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies. | Mol Cancer Ther | 2017 |
| 29206221 | Corrigendum: Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. | Sci Data | 2017 |
| 28636942 | Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres. | Cell Rep | 2017 |
| 28656755 | Microfluidic Separation of Lymphoblasts for the Isolation of Acute Lymphoblastic Leukemia Using the Human Transferrin Receptor as a Capture Target. | Anal Chem | 2017 |
| 27786412 | Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. | Pediatr Blood Cancer | 2017 |
| 26080839 | Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235. | Clin Cancer Res | 2016 |
| 28881577 | A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas. | Oncotarget | 2016 |
| 26438783 | Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma. | Clin Cancer Res | 2016 |
| 26398108 | Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. | Pediatr Blood Cancer | 2016 |
| 27747870 | Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer. | Br J Pharmacol | 2016 |
| 27238606 | Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. | Pediatr Blood Cancer | 2016 |
| 27530131 | Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts. | Mol Cancer Ther | 2016 |
| 27496711 | Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. | Cancer Res | 2016 |
| 27092812 | A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. | Pediatr Blood Cancer | 2016 |
| 26797892 | Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. | Pediatr Blood Cancer | 2016 |
| 25263539 | Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. | Pediatr Blood Cancer | 2015 |
| 26154614 | Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program. | Pediatr Blood Cancer | 2015 |
| 26153194 | Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. | Pediatr Blood Cancer | 2015 |
| 25845499 | Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration. | Exp Cell Res | 2015 |
| 25711293 | Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma. | Cancer Immunol Immunother | 2015 |